Compare CDLR & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CDLR | HROW |
|---|---|---|
| Founded | 2008 | 1998 |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.7B |
| IPO Year | 2023 | 2008 |
| Metric | CDLR | HROW |
|---|---|---|
| Price | $21.67 | $27.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $65.00 |
| AVG Volume (30 Days) | 72.7K | ★ 623.3K |
| Earning Date | 11-23-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 71.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $54.35 | $28.59 |
| Revenue Next Year | $37.14 | $53.17 |
| P/E Ratio | $7.39 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.37 | $26.96 |
| 52 Week High | $30.01 | $54.98 |
| Indicator | CDLR | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 38.54 | 28.20 |
| Support Level | $20.96 | N/A |
| Resistance Level | $22.21 | $35.87 |
| Average True Range (ATR) | 0.49 | 1.32 |
| MACD | -0.05 | -0.08 |
| Stochastic Oscillator | 47.73 | 12.76 |
Cadeler AS is an offshore wind installation vessel contractor. It currently operates various offshore jack-up wind installation vessels, with new builds on order. The Group operates within the market for the transportation and installation of offshore wind turbine generators (WTGs) and their foundations. In addition to wind farm installation, its vessels can perform maintenance, decommissioning, and other general construction tasks within the offshore industry. Cadler's customer base consists of offshore wind farm developers, original equipment manufacturers, and various offshore contractors. Geographically, the Group generates maximum revenue from the United States and the rest from the United Kingdom, Taiwan, Germany, Denmark, Poland, and other regions.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.